Physician profile
David C Chen
NPI 1285184465
$1,797.83
in general payments reported to CMS, 2019-2025
23 companies · $762 in 2025
The $762 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $120 · 2023: $178 · 2024: $558 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.04 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $364.95 | 2025 | Niktimvo, Jakafi |
| Daiichi Sankyo INC. | $248.04 | 2024-2025 | Vanflyta |
| Abbvie INC. | $139.67 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $132.09 | 2021 | |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Sobi, INC | $99.09 | 2024 | |
| Pfizer INC. | $98.14 | 2022-2025 | |
| Dexcom, INC. | $95.41 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $67.59 | 2023-2024 | Gardasil 9, Vaxelis, M-M-R II |
| Regeneron Healthcare Solutions, INC. | $52.57 | 2024 | Libtayo |
| Genentech USA, INC. | $50.56 | 2024 | Venclexta, Polivy |
| Sanofi Pasteur INC. | $50.06 | 2022-2023 | |
| Emd Serono, INC. | $39.78 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.19 | 2023-2024 | |
| Cranial Technologies, INC | $31.70 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.16 | 2024 | |
| Genmab U.S., INC. | $27.58 | 2024 | Epkinly |
| Biohaven Pharmaceutical Holding Company LTD. | $27.08 | 2022 | |
| Pharmaessentia USA Corporation | $25.59 | 2024 | Besremi |
| Amarin Pharma, INC. | $25.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $22.47 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.42 | 2025 | Danziten |
| Novo Nordisk INC | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.